n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Huntington Disease in 1 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chabrier, PE | 1 |
| Demerlé-Pallardy, C | 1 |
| Auguet, M | 1 |
1 review available for n-(3-(aminomethyl)benzyl)acetamidine and Huntington Disease
| Article | Year |
|---|---|
Nitric oxide synthases: targets for therapeutic strategies in neurological diseases.
Topics: Alzheimer Disease; Amidines; Amyotrophic Lateral Sclerosis; Animals; Benzylamines; Brain Injuries; B | 1999 |